By Greg Ryan ( December 4, 2012, 11:01 PM EST) -- Drugmakers that promote their products for off-label uses following the Second Circuit's landmark ruling on Monday could find themselves without their go-to defense in some personal injury lawsuits, attorneys say, since securing preemption when the use of a drug is not federally approved will likely prove a formidable task....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.